18F-DOPA PET/CT at the Forefront of Initial or Presurgical Evaluation of Small-Intestine Neuroendocrine Tumors

Le résumé fourni par la source

To compare the respective value of 68Ga-DOTATOC and 18F-DOPA PET/CT for initial staging or pre-surgical work-up of patients with small intestine neuroendocrine tumors (SiNET). Methods: This is a retrospective, multicenter, non-interventional investigation involving 53 non-operated SiNET patients who underwent both 68Ga-DOTATOC and 18F-DOPA PET/CT within a 6-months interval without therapeutic intervention or change between the two PET/CT studies. Detection rate (DR %) was calculated according to per-region and per-lesion analyses. Sensitivity for primary tumor detection was assessed in 37 operated patients taking surgical results (76 SiNET) as diagnostic gold standard. Results: Each of 68Ga-DOTATOC PET/CT and 18F-DOPA PET/CT individually identified at least one primary SiNET in 92% (34/37) of the patients. Tumor intestinal multifocality was confirmed by histology in 8 patients. 68Ga-DOTATOC and 18F-DOPA PET/CT were concordant positive for tumor multifocality in 5, discordant positive in 2, and concordant negative in 1 case. DR % for subdiaphragmatic nodal metastases on per-region-based analysis was 91 % and 98 % for 68Ga-DOTATOC and 18F-DOPA PET/CT, respectively (P = 0.18). 18F-DOPA PET/CT detected a higher number of abnormal subdiaphragmatic nodes (P = 0.009). Regarding mesenteric nodes only, 18F-DOPA PET/CT detected more positive regions (P = 0.005) and nodal lesions (P = 0.003) than 68Ga-DOTATOC PET/CT, including nodes located at the origin of mesenteric vessels. For detection of distant metastases, 68Ga-DOTATOC and 18F-DOPA PET/CT performed equally on a per-region-based analysis. As compared to 68Ga-DOTATOC, 18F-DOPA PET/CT detected more hepatic (p<0.001), peritoneal (p<0.001), and lung metastases (p<0.001). Conclusion:18F-DOPA PET/CT detects more lesions than 68Ga-DOTATOC PET/CT in studied patients. Their respective role should be discussed in terms of disease staging and treatment selection.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.